|

Long-term Longitudinal Imaging of Presynaptic Terminals in PD

RECRUITINGN/ASponsored by Universitaire Ziekenhuizen KU Leuven
Actively Recruiting
PhaseN/A
SponsorUniversitaire Ziekenhuizen KU Leuven
Started2025-07-16
Est. completion2027-12
Eligibility
Age30 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06875765

Summary

AIM: To investigate whether SV2A loss spreads from brainstem to cerebral cortex with progression of Parkinson's disease (PD) and to determine whether longitudinal cortical SV2A loss correlates with cognitive decline in PD. STUDY DESIGN: The investigators will re-invite participants (both patients with PD and healthy controls) of a previous longitudinal study (NCT04243304, S61477) to undergo evaluation approximately 7 years after the initial baseline study visit (i.e. on average 10 years since the first motor symptoms). All participants will undergo clinical assessment of motor and non-motor symptoms (including cognitive testing), as well as 11C-UCB-J PET-CT (targeting synaptic density marker SV2A), 18F-FE-PE2I PET-CT (targeting DAT) and brain MRI.

Eligibility

Age: 30 Years+Healthy volunteers accepted
Inclusion Criteria:

* Participation in study S61477 (NCT04243304)

Exclusion Criteria:

* Neuropsychiatric diseases (unrelated to PD for PD patients)
* Major internal medical diseases
* History of alcohol or drug abuse
* Relevant abnormalities on MR brain
* Contraindications for MR
* Pregnancy or breastfeeding
* Previous participation in other research studies involving ionizing radiation with \> 1 mSv over past 12 months.

Conditions2

Parkinson DiseaseParkinson's Disease

Browse More Trials

Parkinson's Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.